Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery

Abstract

Nepafenac ophthalmic suspension 0.1% was safe and effective for preventing and treating ocular inflammation and pain associated with cataract surgery.

Efficacy and Safety of Sustained Release Dexamethasone for the Treatment of Ocular Pain and Inflammation after Cataract Surgery: Results from Two Phase 3 Studies

“…It should be noted that this trial consisted of only 60 patients, and as a result was not powered for statistical significance. The Phase 3 study protocol was revised based on data from the Phase 2 and other studies showing significant differences with 14-or 15-day endpoints using either steroids [24] or non-steroidal anti-inflammatory drugs [25,26].…”

In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac

“…Lane et al 26 recently published the Nevanac pivotal regulatory trial using preoperative 3 times daily dosing for 1 day in all patients who had cataract surgery. These results support Nevanac's safety and efficacy in the control of pain and inflammation associated with cataract surgery.…”

Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification

“…15 The question remains whether the pro-NSAID nepafenac, with its purported improved ocular penetration, is superior in this context. 9,16 One major aspect that has been missing in the aforementioned literature is the evaluation of health-related quality-of-life (HRQOL). Although numerous topical NSAID medications are available, little is known about their effect on the HRQOL of patients having cataract surgery.…”